Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant’s last stand on paclitaxel

This article was originally published in The Gray Sheet

Executive Summary

Company's paclitaxel-eluting stent program achieves closure with federal appeals court affirmation of lower court ruling that Cook's deal with Guidant violated a co-exclusive license agreement among Boston Scientific, Cook and Angiotech. The program already had been terminated due to poor DELIVER study results; in January, Guidant scuttled a proposed merger with Cook. Guidant is exploring an everolimus-eluting stent (1"The Gray Sheet" Jan 6, 2003, p. 4). Boston Scientific submits the fifth and final PMA module for its Taxus paclitaxel-eluting stent...

You may also be interested in...



Cook Reconsiders Logic Of Drug-Eluting Stents As Guidant Deal Unravels

Cook Group is considering re-starting the 1,200-patient, six-center PATENCY pivotal trial of its Logic PTX paclitaxel-eluting coronary stent

GT Medical Technologies Raised $16M In Funding To Expand Brain Tumor Therapy

The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.

AMS Acquires Raleigh Adhesive Coatings Company For £22M ($29M) In Cash

Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business. 

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel